Extracellular vesicle PD‑L1 dynamics predict durable response to immune‑checkpoint inhibitors and survival in patients with non‑small cell lung cancer
Metadatos
Mostrar el registro completo del ítemEditorial
BMC
Materia
Extracellular vesicles PD-L1 Biomarkers Immunotherapy NSCLC
Fecha
2022-06-02Referencia bibliográfica
de Miguel-Perez, D... [et al.]. Extracellular vesicle PD-L1 dynamics predict durable response to immune-checkpoint inhibitors and survival in patients with non-small cell lung cancer. J Exp Clin Cancer Res 41, 186 (2022). [https://doi.org/10.1186/s13046-022-02379-1]
Patrocinador
Center for Thoracic Oncology Icahn School of Medicine at Mount Sinai; Borsa Dottorati FSE XXXII ciclo Unime; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) P30CA016672; University of Pittsburgh Hillman Cancer Center; Hillman Cancer Center's NCI Cancer Center Support Grant (CCSG) P30CA047904; A.S.S.O. (Associazione Siciliana Sostegno Oncologico) Onlus; National Cancer Institute-Cancer Center Support Grant (CCSG) P30CA134274; Merck & CompanyResumen
Background: Immune-checkpoint inhibitors (ICIs) changed the therapeutic landscape of patients with lung cancer.
However, only a subset of them derived clinical benefit and evidenced the need to identify reliable predictive biomarkers.
Liquid biopsy is the non-invasive and repeatable analysis of biological material in body fluids and a promising
tool for cancer biomarkers discovery. In particular, there is growing evidence that extracellular vesicles (EVs) play
an important role in tumor progression and in tumor-immune interactions. Thus, we evaluated whether extracellular
vesicle PD-L1 expression could be used as a biomarker for prediction of durable treatment response and survival in
patients with non-small cell lung cancer (NSCLC) undergoing treatment with ICIs.
Methods: Dynamic changes in EV PD-L1 were analyzed in plasma samples collected before and at 9 ± 1 weeks during
treatment in a retrospective and a prospective independent cohorts of 33 and 39 patients, respectively.
Results: As a result, an increase in EV PD-L1 was observed in non-responders in comparison to responders and was
an independent biomarker for shorter progression-free survival and overall survival. To the contrary, tissue PD-L1
expression, the commonly used biomarker, was not predictive neither for durable response nor survival.
Conclusion: These findings indicate that EV PD-L1 dynamics could be used to stratify patients with advanced NSCLC
who would experience durable benefit from ICIs.